Compared anti-HER2 monotherapies and combination regimens, an analysis based on the FAERS showed that trastuzumab and pertuzumab/T-DM1 had higher odds of heart failure reporting than other anti-HER2 therapies [22]. The gene discussed is ERBB2; the disease is heart failure.